Newtyn Management, LLC - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 93 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2019. The put-call ratio across all filers is 0.44 and the average weighting 0.8%.

Quarter-by-quarter ownership
Newtyn Management, LLC ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$15,892,663
-6.4%
1,841,560
+12.3%
3.92%
-2.2%
Q2 2023$16,978,720
+2.2%
1,640,456
+7.1%
4.01%
+22.9%
Q1 2023$16,611,513
+2.1%
1,531,015
+5.6%
3.26%
-2.8%
Q4 2022$16,269,000
-35.7%
1,450,000
-41.9%
3.36%
-39.6%
Q3 2022$25,308,000
+37.1%
2,495,860
+22.5%
5.56%
+58.8%
Q2 2022$18,463,000
+40.5%
2,037,825
+48.2%
3.50%
+11.1%
Q1 2022$13,145,000
+19.0%
1,375,000
+37.5%
3.15%
+7.3%
Q4 2021$11,050,000
+1424.1%
1,000,000
+920.9%
2.93%
+1419.7%
Q3 2021$725,000
-83.8%
97,955
-43.5%
0.19%
-53.4%
Q4 2019$4,487,000
+261.6%
173,300
+172.1%
0.41%
+253.8%
Q3 2019$1,241,00063,6810.12%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q3 2019
NameSharesValueWeighting ↓
Woodford Investment Management Ltd 11,213,879$254,331,00030.84%
Cormorant Asset Management, LP 1,300,000$29,484,0002.18%
Baupost Group 9,309,168$211,132,0001.85%
SENZAR ASSET MANAGEMENT, LLC 27,397$621,0001.79%
ARMISTICE CAPITAL, LLC 1,180,000$26,762,0001.75%
Old West Investment Management, LLC 111,101$2,519,0001.27%
Chescapmanager LLC 403,321$9,147,0001.06%
Virtus ETF Advisers LLC 30,055$682,0000.60%
Rock Springs Capital Management LP 652,600$14,801,0000.57%
Foundation Asset Management, LP 27,154$616,0000.53%
View complete list of THERAVANCE BIOPHARMA INC shareholders